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Abstract
Peritoneal dialysis (PD) involves solute and water transport across a semipermeable 
membrane that separates fluid compartments. Peritonitis is a serious complication of 
peritoneal dialysis that results in considerable morbidity and health care costs. It also sig-
nificantly distorts the normal anatomy of the peritoneal membrane causing transient and 
long-term adverse events. Bacterial as well as fungal organisms can cause peritonitis and 
sometimes cultures can be negative. As much as 5–16% of deaths occur in PD even though 
the rate of infections has been in decline in last few years. Below we will be reviewing risk 
factors, host’s immune defenses, prevention, diagnosis and evidence-based treatment, 
types of peritonitis with a role of prophylactic antibiotics for PD peritonitis.
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1. Introduction
Peritoneal dialysis is one of two principal modalities for renal replacement therapy and has 
been utilized extensively in many countries including Hong-Kong, Mexico, Thailand, Canada, 
the Netherlands, Australia and Denmark. One of the commonest complications of peritoneal 
dialysis is peritonitis, which leads to increased health care costs, hospitalizations, catheter 
removal, malnutrition and peritoneal membrane damage. Survival on PD continues to improve 
in the United States, with overall survival as good as for similar patients during in-center 
hemodialysis (HD). Nonetheless, approximately 20% of patients undergo a modality switch 
to HD during their first year on PD due to modality or access-related infections. Repeated 
episodes of bacterial peritonitis are a major factor leading to the loss of peritoneal function 
and resulting in failure of PD [1, 2]. PD peritonitis seldom evolves into systemic bacteremia or 
fungemia and the infection remains as a rule confined to the peritoneal cavity. With increased 
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peritoneal permeability during peritonitis, a reduction in ultrafiltration occurs, which would 
lead to fluid accumulation and potential symptomatic volume overload.
2. Relative immunosuppression in end-stage renal disease
Peritoneal leucocytes are predominant players in combating bacteria in the peritoneal cavity. 
Most dialysate solutions have an unphysiological pH of 5, which might inhibit the phagocytic 
ability of these leucocytes. End-stage renal disease (ESRD) impairs both innate and adaptive 
immune responses. Decreased endocytosis and impaired maturation of monocytes and dendritic 
cells are demonstrated in the uremic state, contributing to an increased susceptibility to infections 
[3, 4]. Impaired maturation of thymic lymphocytes and impaired functions of toll-like receptors 
(which provide protection against infections) also increase the susceptibility to infections.
3. Strategies for prevention of peritonitis
Peritonitis with automated peritoneal dialysis (APD) and continuous ambulatory peritoneal 
dialysis (CAPD) are not different. All PD programs in the United States monitor the incidence 
of peritonitis (rates should be no higher than 0.5 episodes per year), which helps programs 
target interventions when rates go high. The Baxter database of 35 US centers reports 3111 
episodes of peritonitis with an overall peritonitis rate of 1 per 33 patient months, while the 
overall exit site infection (ESI) rate is 1 per 65 patient months. Reported causes of peritonitis 
include contamination during treatments, untreated PD catheter tunnel or exit point infec-
tions, transmural migration of organisms from the gut due to diverticulitis, systemic infections 
and procedural instrumentation (gynecologic, dental or post-colonoscopy). Touch contami-
nation is the most common source followed by ESI and tunneled catheter infections. Jassal 
reported an association between a treated ESI and subsequent PD peritonitis [5]. One of the 
earliest multi-center randomized clinical trials comparing the Y connector disinfectant system 
to standard systems showed superiority and decreased infections with Y connectors using 
“flush before fill” techniques [6]. The practice has become widespread since. Appropriate 
interventions including educating and teaching patients’ strict aseptic precautions (including 
hand hygiene) during exchanges along with intensive retraining and reinforcement of sterile 
techniques might have led to a decrease in infections.
In the last 2 decades we have realized that exit site and tunneled infections contribute exten-
sively to peritonitis risk in the days immediately following the diagnosis. Treatment of an 
exit site infections are especially critical as the peritonitis risk is increased >10-fold in the first 
15 days with a progressive decrease but continuous presence up to 2–3 months [5]. These 
observations resulted in the practice of daily topical application for prophylactic antibiotic 
(mupirocin or gentamicin) creams or ointments to the catheter exit sites and prompt treatment 
of ESI worldwide. A double-blind randomized trial showed that the daily application of gen-
tamicin cream on the exit site resulted in a 57%-reduction in ESI and a 35%-reduction in peri-
tonitis compared with mupirocin. Gentamycin, a bactericide, also prevented infections with 
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Staphylococcus aureus and Pseudomonas aeruginosa [7]. At least 3 trials have shown that topical 
exit site disinfection with povidone-iodine did not reduce the risk of peritonitis compared to 
soap and water or no treatment [8, 9]. Randomized controlled trial (RCT) of mupirocin to a 
“triple-antibiotic” combination (bacitracin, gramicidin and polymyxin B) showed non-supe-
riority to mupirocin and concern for fungal colonization of exit site with triple-antibiotic use. 
Further, exit site trauma should be treated with antibiotic prophylaxis. High levels of soluble 
C5b-9 in the dialysate predict poor prognosis during peritonitis [10]. Antifungal prophylaxis 
with oral fluconazole (200 mg orally on day one, then 100 mg/day for 1 week after completion 
of treatment) or nystatin (500,000 IU orally three times a day while on antibiotics) can be con-
sidered with concurrent antibiotic use, while treating peritonitis to prevent fungal peritonitis. 
There is uncertainty regarding fluconazole for prophylaxis against fungal peritonitis but one 
RCT supported the use of nystatin [11].
Antimicrobial actions of peritoneal macrophages are enhanced by both calcium and vita-
min D. Kerschbaum reported that calcitriol decreased the risk of peritonitis and improved 
survival [12]. Even though there were initial reports of low peritonitis rates with low glu-
cose-degradation-product (GDP) solutions, a subsequent meta-analysis of 6 randomized 
controlled trials concludes uncertainty at this time [13, 14]. Gastroenteritis and hypokalemia 
Social/environmental
• Smoking
• Living distantly from PD unit
• Pets
Medical
• Obesity
• Depression
• Hypokalemia
• Hypoalbuminemia
• Absence of vitamin D supplementation
• Invasive interventions (e.g. colonoscopy)
Dialysis-related
• Prior hemodialysis
• PD against patient’s choice
• Training
• Bioincompatible fluids
• Wet contamination
Infection-related
• Nasal Staphylococcus aureus carrier status
• Previous exit site infection
Adapted from Cho [19] and ISPD 2016 guidelines [20].
Table 1. Modifiable risk factors of peritonitis.
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have been linked to peritonitis risk, though there is no evidence that treating these would 
decrease said risk. Table 1 lists modifiable risk factors for peritonitis. For hypokalemia man-
agement and prophylaxis, potassium-sparing diuretics are effective even in PD patients 
[15–17]. Most nephrologists agree on the importance of avoiding constipation to prevent 
peritonitis and monitoring peritonitis rates and trends in their programs with intensive 
retraining in patients with frequent episodes of peritonitis. The International Society of 
Peritoneal Dialysis (ISPD) recommends prophylactic systemic antibiotics immediately prior 
to catheter insertion on the basis of 4 RCT. Placement of PD catheters with a downward-
facing exit site decreases risk. Nevertheless, the 2017 ISPD guidelines concluded that none 
of the catheter placement techniques are superior in the prevention of any catheter-related 
infection [18]. The use of topical mupirocin in patients with colonization of nares is rec-
ommended before PD catheter insertion. The role of prophylactic antibiotics in preventing 
peritonitis is discussed in detail below.
4. Role of prophylactic antibiotics prior to procedures
Invasive interventional procedures like colonoscopy, hysteroscopy, sigmoidoscopy, cystos-
copy, cholecystectomy or dental procedures show a significant risk of progressing to peritoni-
tis; hence the ISPD recommendation of preprocedural antibiotics in such cases. Even though 
2005 ISPD guidelines recommended prophylaxis with minimal evidence, Yip et al. [21] in 2007 
conducted a single-center study in which peritonitis occurred in 6.3% of 79 colonoscopies per-
formed without antibiotic prophylaxis and none performed with antibiotic prophylaxis. Since 
then, most programs have been implementing preprocedural antibiotics. Gadallah’s study of 
221 patients concludes that single-dose vancomycin is superior to single-dose cefazolin and 
reduces peritonitis prior to PD catheter insertion [22]. Table 2 lists appropriate antibiotics 
before procedures, which are purely opinion-based.
• Exit site care with topical mupirocin or gentamycin in all patients
• Dental procedures
 ○ Amoxicillin 2.0 g 2 h before
• Colonoscopy or GYN procedures:
 ○ Aminoglycoside overnight + oral metronidazole or ampicillin 1 g PO
 ○ Fluconazole added in GYN procedures
 ○ Perform procedures with dry abdomen and for a day afterwards
• Antifungals when on systemic antibiotics to prevent secondary peritonitis
Adapted from ISPD [18].
Table 2. Preprocedural antibiotic prophylaxis to prevent peritonitis.
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5. Presentation, diagnosis and management of peritonitis
Peritoneal dialysis patients have catheter embedded in their abdomen all the way to peri-
toneum. Infection can occur anywhere between the exit site of catheter, the tunneled area 
and the peritoneum. PD-related peritonitis is a local infection and only 20% of patients with 
peritonitis end up hospitalized. Catheters can get colonized with organisms, which some-
times form a biofilm. Mild trauma to the exit site may also cause peritonitis when conditions 
are favorable, as is the case with colonization and depressed immunity. Exit site infections 
could progress to tunneled infections and peritonitis if left untreated in most cases. Since 
most programs use antimicrobial prophylaxis, exit site infections are on the decline. ISPD 
2017 recommends that the rate of catheter-related infections should be presented as numbers 
of episodes per year. Patients usually present with abdominal symptoms including abdomi-
nal pain, discomfort, vomiting or cloudy effluent. Fever with tachycardia and florid sepsis is 
seldom present. Patients should be asked about contamination during exchanges, signs of exit 
site infection, constipation, recent procedures, hospitalizations and recent antibiotic use for 
other systemic infections. A physical exam could reveal abdominal tenderness, redness at the 
exit site and should look for evidence of hernias.
Once peritonitis is suspected, empiric antibiotics should be started as soon as possible after 
drawing dialysate for cell count, culture and Gram stain. ISPD recommends collecting cul-
tures of 5–10 mL of effluent in blood culture bottles. Peripheral blood cultures are taken only 
if the patient looks toxic and septic. Diagnosis requires that cell count be >100 cells/mm3 with 
appropriate symptoms. If >50% of WBCs are polymorph mononuclear leucocytes (PML), it 
is very likely that the patient has bacterial peritonitis even if the total cell count is <100 cells/
mm3. It is recommended in APD to collect PD fluid after a dwell time of at least 2 h. One 
should be able to read a newspaper when effluent bag is laid over, which is a simple inexpen-
sive test to see whether dialysate is cloudy, or not. Only cell count with appropriate cultures 
can confirm diagnosis though. Conditions that lead to cloudy effluent are listed in Table 3 and 
criteria for diagnosis of peritonitis are listed in Table 4.
Most PD-related infectious peritonitis will have amylase levels of <50 IU/L in effluent and 
pancreatitis or other intra-abdominal pathology showing >50 IU/L, but one needs to note 
that icodextrin interferes with amylase assay and is not reliable. Systemic antibiotics are usu-
ally not needed since infection is local. Antibiotics via dialysate can be given intermittently 
every few days or continuously with every bag; programs may differ in their approaches. 
Nevertheless, if the patient is unresponsive to the intermittent approach for 3–4 days, a con-
tinuous approach is recommended. The decision to admit to inpatient service is generally 
dictated by the patient’s general condition and degree of illness, rather than the underlying 
diagnosis of suspected PD-associated peritonitis. Most of these events will be treated in out-
patient care.
Initial therapy with broad spectrum antibiotics is recommended as soon as possible for cov-
ering both Gram-positive and -negative organisms until culture results are available. For 
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Gram-positive organisms, vancomycin (with history of MRSA) or cephalosporins are rec-
ommended, as well as and ciprofloxacin, ceftazidime, cefepime or aminoglycosides tailored 
depending on whether the patient has significant residual renal function. Barretti conducted 
a proportionate meta-analysis and found that vancomycin and teicoplanin with ceftazidime 
were found to be superior to other regimens [23]. One needs to keep in mind sensitivities, 
common resistance patterns locally, the patient’s residual renal function and a history of 
peritonitis. The opacity of the fluid is expected to change from cloudy to clear in around 
48–72 h. Figure 1 lists the initial approach to peritonitis. In most cases, culture positivity 
can be established within 3 days. When the causative organism has been identified, subse-
quent cultures may be performed for monitoring, but when cultures remain negative after 
3–5 days of incubation, cell count and differential, fungal, and mycobacterial cultures are to 
be repeated. Every organism’s interaction with the immune system is unique. Lin’s study 
of 52 patients provide evidence that local “immune fingerprints,” representative of specific 
organisms, are evident in said patients and differentiate between culture-negatives, Gram-
positives or -negatives [24]. These immunologic biomarkers seem promising even though 
point of care tests have not yet been used widely.
Even though vancomycin is the preferred empiric therapy in methicillin-resistant Staphylococcus 
aureus (MRSA), there is no difference in cure rates for vancomycin and cefazolin when an 
appropriate cephalosporin dose is used in the context of methicillin-sensitive Staphylococcus 
aureus. It has been speculated that local (compartmental) antibiotic concentration with IP 
administration will greatly exceed concentrations serum concentrations, on which the general 
1. Clinical, i.e. abdominal pain with our without cloudy dialysate
2. Effluent white cell count >100/μL or >0.1 × 109/L (dwell time of at least 2 h), and >50% polymorphs
3. Culture positive dialysate
Adapted from ISPD [20]. At least 2 of the above should be positive to diagnose peritonitis.
Table 4. Diagnosis of peritonitis.
Infectious peritonitis
Pancreatitis
Chemical peritonitis (medications, e.g., dihydropyridine calcium channel blockers [nifedipine, lercanidipine]))
Malignant ascites
Effluent eosinophilia
Sclerosing peritonitis
Chylous ascites
Specimen from dry abdomen
Table 3. Differential diagnosis of cloudy effluents.
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concept of sensitivity is based upon. Ceftazidime, cefepime, aminoglycosides (e.g. gentamicin 
or netilmicin) or a carbapenem cover Gram-negatives adequately. Fluoroquinolones could be 
used if cultures show sensitivity, but there is an increased risk of Achilles tendon rupture in 
renal failure with fluoroquinolones. In patients allergic to cephalosporin, aztreonam could be 
used. Aminoglycosides demonstrate excellent Gram-negative activity and could be used in 
resource-poor nations where cost would be a barrier, as there is no evidence that short courses 
of aminoglycosides accelerate the loss of residual renal function [25] unless used for more 
than 3 weeks. Systemic absorption with a prolonged use of IP gentamycin can cause toxicity 
and might not correlate with systemic levels.
ISPD recommendations regarding the dosing of intraperitoneal (IP) antibiotics are listed in 
Table 5. These antibiotics should be administered using sterile techniques and IP use results 
in high local drug levels and is preferable to IV administration as peritonitis is mostly local 
and antibiotics are delivered at high concentration to the infected compartment, including to 
ensure the penetration of infected biofilms on peritoneal catheters [26]. Intermittent dosing 
should be dwelled for at least 6 h to allow for adequate absorption. IP vancomycin is dosed 
every 4–5 days, keeping serum trough levels above 15 μg/mL even though most programs do 
not check systemic levels. For patients on APD, intermittent doses of IP can be administered, 
Figure 1. Initial approach to peritonitis.
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Aminoglycosides Intermittent (1 exchange daily) Continuous (all exchanges)
Amikacin 2 mg/kg daily LD 25 mg/L, MD 12 mg/L
Gentamicin 0.6 mg/kg daily LD 8 mg/L, MD 4 mg/L
Netilmicin 0.6 mg/kg daily MD 10 mg/L
Tobramycin 0.6 mg/kg daily LD 3 mg/kg, MD 0.3 mg/kg
Cephalosporins
Cefazolin 15–20 mg/kg daily LD 500 mg/L, MD 125 mg/L
Cefepime 1000 mg daily LD 250–500 mg/L, MD 100–125 mg/L
Cefoperazone No data LD 500 mg/L, MD 62.5–125 mg/L
Cefotaxime 500–1000 mg no data on daily dosage
Ceftazidime 1000–1500 mg daily LD 500 mg/L, MD 125 mg/L
Ceftriaxone 1000 mg daily No data
Penicillins
Penicillin G No data LD 50,000 unit/L, MD 25,000 unit/L
Amoxicillin No data MD 150 mg/L
Ampicillin No data MD 125 mg/L
Ampicillin/sulbactam 2 g/1 g every 12 h LD 750–100 mg/L, MD 100 mg/L
Piperacillin/tazobactam No data LD 4 g/0.5 g, MD 1 g/0.125 g
Others
Aztreonam 2 g daily LD 1000 mg/L, MD 250 mg/L
Ciprofloxacin No data MD 50 mg/L
Clindamycin No data MD 600 mg/bag
Daptomycin No data LD 100 mg/L, MD 20 mg/L
Imipenem/cilastatin 500 mg in alternate exchange LD 250 mg/L, MD 50 mg/L
Ofloxacin No data LD 200 mg, MD 25 mg/L
Polymyxin B No data MD 300,000 unit (30 mg)/bag
Quinupristin/dalfopristin 25 mg/L in alternate exchangea No data
Meropenem 1 g daily No data
Teicoplanin 15 mg/kg every 5 days LD 400 mg/bag, MD 20 mg/bag
Vancomycin 15–30 mg/kg every 5–7 daysb LD 30 mg/kg, MD 1.5 mg/kg/bag
Antifungals
Fluconazole IP 200 mg every 24–48 h No data
Voriconazole IP 2.5 mg/kg daily No data
Courtesy of ISPD 2016 [20].
aGiven in conjunction with 500 mg intravenous twice daily.
bSupplemental doses may be needed for APD patients.
Table 5. Intraperitoneal antibiotic dosing recommendations for treatment of peritonitis.
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Drug Dosing
Anti-bacterials
Ciprofloxacin Oral 250 mg BD
Colistin IV 300 mg loading, then 150–200 mg daily
Ertapenem IV 500 mg daily
Levofloxacin Oral 250 mg daily
Linezolid IV or oral 600 mg BD
Moxifloxacin Oral 400 mg daily
Rifampicin 450 mg daily for BW <50 kg; 600 mg daily for BW ≥50 kg
Trimethoprim/sulfamethoxazole Oral 160 mg/800 mg BD
Antifungals
Amphotericin IV test dose 1 mg; starting dose 0.1 mg/kg/day over 6 h; target dose 
0.75–1.0 mg/kg/day
Caspofungin IV 70 mg loading, then 50 mg daily
Fluconazole Oral 200 mg loading, then 50–100 mg daily
Flucytosine oral 1 g/day
Posaconazole IV 400 mg every 12 h
Voriconazole Oral 200 mg every 12 h
Adapted from ISPD 2016 [20]. BD, twice a day; IV, intravenous; BW, body weight.
Table 6. Systemic antibiotic dosing recommendations for the treatment of peritonitis.
Organism Duration of treatment
Coagulate negative Staphylococcus aureus 2 Weeks
Staphylococcus aureus 3 weeks
Streptococcus 2 weeks
Enterococcus 3 weeks
Most Gram-negative bacilli 3–4 weeks
Stenotrophomonas species 3–4 weeks
Pseudomonas 3–4 weeks
Mixed Gram-positive and Gram-negative organisms 3 weeks
Multiple Gram-positive organisms 3 weeks
Fungal organisms (immediate catheter removal) 2–3 weeks post catheter removal
Corynebacterium species 3 weeks
Table 7. Duration of treatment of PD peritonitis by organism type.
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utilizing a day dwell of APD, or alternatively, a temporary change to CAPD might become 
necessary. Heparin at a dose of 500 units/L may be added to the PD fluid to decrease fibrin 
formation. In patients with biofilm in the catheter, the administration of oral rifampicin and 
IP urokinase to disrupt the catheter-associated biofilm resulted in catheter salvage in 64% 
of cases [27]. Chow analyzed outcomes of 565 consecutive episodes of peritonitis in relation 
to dialysate cell counts and concluded that effluent WBC count ≥1090/mm3 on day 3 was an 
independent prognostic marker for treatment failure [28]. The dosing of systemic antibiotics 
per ISPD recommendation is listed in Table 6. After empiric initial treatment, antibiotics are 
tailored depending on culture results with a duration of treatment determined by the type of 
organism affected (Table 7).
Mycobacterial infections are rare but present a challenge to diagnosis and should therefore 
be considered in the appropriate patients (living in third world or developed countries with 
endemic areas or history of travel) with persistent symptoms despite optimal periods of time 
on antibiotics. When effluent cultures are negative by day 3 (culture-negative peritonitis), cell 
count with differential should be repeated; if symptoms persist, effluent should be tested for 
tuberculous and nontuberculous mycobacteria in conjunction with a continuation of antibiot-
ics for Gram-positive organisms. Aminoglycoside antibiotics should be discontinued if the 
patient remains asymptomatic with negative cultures. Native kidneys can clear antibiotics 
and there is higher risk of treatment failure in patients with significant residual renal function 
especially in Gram-positive and culture-negative patients [29]. Guidelines for the removal of 
catheters are listed in Table 8.
6. Standard definition with types of peritonitis (not based on type of 
organism)
6.1. Recurrent
Occurs within 4 weeks of completed therapy of previous episode with new organism. Carries 
worse prognosis than relapsing and repeat peritonitis. If polymicrobial or enteral organisms 
are seen, would need surgical evaluation and appropriate imaging of abdomen. Catheter 
removal should be considered.
Fungal peritonitis
Failed treatment for mycobacterial and polymicrobial infections
Refractory peritonitis
Relapsing peritonitis
Refractory exit site and tunneled infections
Table 8. Indications for catheter removal.
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6.2. Relapsing
Occurs within 4 weeks of completion of therapy of previous episode with the same organ-
ism. Lower rate of cure reported and catheter removal should be considered, especially if 
there is a suspected bacterial colonization of catheter. Sonography of catheter tunnel is also 
recommended.
6.3. Repeat
Occurs more than 4 weeks post-therapy of a prior episode with the same organism. Risk is 
highest 3 months after an episode and remains high for next 24 months [19]. Revaluate anti-
biotic dosage and optimal duration of treatment. Further management depends on antibiotic 
sensitivity and might consider adding a second antibiotic for synergy although no evidence 
exists for this recommendation. Catheter removal could be considered depending on clinical 
status of patient.
6.4. Refractory
Effluent fails to clear after 5 days of appropriate therapy. Treatment includes immediate 
removal of PD catheter and intravenous antibiotics.
6.5. Catheter-related peritonitis
Exit site or tunnel infection progressing to peritonitis with the same organism. Sonogram of 
catheter tunnel if no signs of tunneled infection. Exit site infections that do not progress to 
peritonitis can be treated with oral antibiotics. If refractory exit site or tunneled infection is 
diagnosed, one should consider removal of the PD catheter.
6.6. Eosinophilic peritonitis
Cloudy effluent with >15% eosinophils. Could be seen in parasitic, tuberculous or fungal 
infections, or during recovery from bacterial peritonitis. Also seen with allergy to components 
of dialysate or catheter material and is usually self-limited needing no treatment, except with 
severe symptoms where treatments including steroids have been tried.
7. Summary
Peritoneal dialysis can cause infectious and noninfectious complications and peritonitis is 
one of the most common infectious complications. Peritonitis causes alteration of membrane 
transport characteristics leading to ultrafiltration failure and, with repeated episodes, will 
evolve into encapsulating peritoneal sclerosis. Multiple hospitalizations, transfer to hemo-
dialysis and malnutrition-related complications could result in increasing health care costs 
in an era where pay for performance is advocated. There has been an increasing trend in 
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Gram-negative infections and decrease in Gram-positive infections [30, 31]. Intensive quality 
improvement projects, root cause analysis of adverse events, aggressive retraining and other 
prevention strategies discussed above should be implemented to decrease a potentially pre-
ventable adverse event and achieve improved outcomes.
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